Novel Treatment Targets for Hemophilia A and AML

Novel Treatment Targets for Hemophilia A and AML

Author: American Society of Hematology December 25, 2025 Duration: 23:42

In this week's episode, Blood editor Dr. James Griffin interviews authors Drs. Vincent Muczynski and Mark Geyer on their latest research published in Blood. Dr. Muczynski's research asks if there could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Dr. Geyer then explores CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. Both studies explore finding novel targets for these powerful treatment modalities. 


Featured Articles:


Produced by the American Society of Hematology, the Blood Podcast serves as an audio companion to the groundbreaking research found in its namesake journal. Each episode delves into the latest published studies, translating complex findings on blood disorders, cancers, and immune system functions into accessible discussions. You'll hear directly from the researchers and clinicians who are shaping the field, as they break down their methodologies, interpret results, and explore the real-world implications for patient care. This isn't just a summary; it's a critical conversation that examines the how and why behind the science, offering context that the printed page alone cannot provide. Whether you're a practicing hematologist, a trainee in the field, or simply fascinated by the intricate world of human biology, this podcast provides a vital stream of knowledge. It connects the dots between laboratory discovery and clinical practice, all while exploring topics that span from foundational biology to cutting-edge therapeutic advances. Tune in for a thoughtful analysis that makes the latest hematology research comprehensible and immediately relevant to your work or curiosity.
Author: Language: English Episodes: 50

Blood Podcast
Podcast Episodes
Dose Makes the Cure: Venetoclax in Ph- ALL [not-audio_url] [/not-audio_url]

Duration: 14:21
In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Acad…
MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow [not-audio_url] [/not-audio_url]

Duration: 24:34
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Thomas Milne and Dominique Bonnet on their latest articles published in volume 147 issue 24 of Blood. Dr. Milne discusses how transcription factors s…
Predictive Markers of Glofitamab Resistance in R/R B-NHL [not-audio_url] [/not-audio_url]

Duration: 15:41
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Camille Laurent and Christine Bezombes on their latest article published in Blood titled "Patient-derived lymphoma spheroids reveal predictive markers…
FLT3-ITD microclones in AML and Results from the RESET-PV trial [not-audio_url] [/not-audio_url]

Duration: 13:48
In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in y…
Initial CHORUS data on HHT and ASH HematOmics Program [not-audio_url] [/not-audio_url]

Duration: 26:14
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first re…